Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

REVEALED: 5 | Rare Historical Photos

AMTI: AMTI is Underappreciated

By Brad Sorensen, CFA NASDAQ:AMTI READ THE FULL AMTI RESEARCH REPORT

Benzinga

RGC: Regencell Bioscience - Investigational Liquid-Formula RGC-COV19™ Shows Promise in Eliminating COVID-19 Symptoms

By Beth Senko, CFA NASDAQ:RGC

Benzinga

BTAI: IGALMI™ Approved by the FDA…

By David Bautz, PhD NASDAQ:BTAI READ THE FULL BTAI RESEARCH REPORT

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

DSS: DSS Starts to Generate Revenues From New Ventures and Hits Cash Flow Breakeven in Q4

By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT

Benzinga

MNOV: Genzyme Patent Litigation Could Lead to Significant Payout…

By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT

Benzinga

MITI: Mitesco, Inc. – A Great Set-Up for 2022

By Beth Senko, CFA OTC:MITI READ THE FULL MITI RESEARCH REPORT

Benzinga

WKSP: April Update

By Thomas Kerr, CFA NASDAQ:WKSP READ THE FULL WKSP RESEARCH REPORT

Benzinga

Read news from The Economist, FT, and more,
with one subscription

RFHRF: Renforth Resources Releases Assay Results of December's 7-hole Drilling Program Targeting Victoria West on the Surimeau District Property.

By Steven Ralston, CFA OTC:RFHRF | CSE:RFR

Benzinga

ENSC: Ensysce Releases Encouraging Financials

By Brad Sorensen, CFA NASDAQ:ENSC READ THE FULL ENSC RESEARCH REPORT

Benzinga

CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Benzinga

GBS: Institutional Review Board Approval for Glucose

By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT

Benzinga

BCLI: Awaiting Clarity on Regulatory Environment Before Deciding on Next Steps for NurOwn®…

By David Bautz, PhD NASDAQ:BCLI READ THE FULL BCLI RESEARCH REPORT

Benzinga

RCRT: Recruiter.com Gets Off to a Slower Start in 2022 as Recruiters Need to Redeploy

By Lisa Thompson NASDAQ:RCRT READ THE FULL RCRT RESEARCH REPORT

Benzinga

TENX: 2021 Financial and Operational Review

By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

MITO: Stealth BioTherapeutics' Treatments Gain Momentum

By Brad Sorensen, CFA NASDAQ:MITO READ THE FULL MITO RESEARCH REPORT

Benzinga

LGVN: LGVN Publishes Positive Alzheimer's Results

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga

DYLLF: Deep Yellow Limited and Vimy Resources Agree to Merge. Attributable Resources Expand to 389 Mlbs. Deep Yellow to have multi-jurisdictional flagship projects in Namibia and Australia.

By Steven Ralston, CFA OTCQX:DYLLF | ASX:DYL.AX

Benzinga

EMMA: Emmaus Sickle Cell Treatment Expands Reach

By Brad Sorensen, CFA OTC:EMMA READ THE FULL EMMA RESEARCH REPORT

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs

By Thomas Kerr, CFA NASDAQ:COCP READ THE FULL COCP RESEARCH REPORT

Benzinga

YTRA: Yatra Online Files to IPO on India Exchanges

By Lisa Thompson NASDAQ:YTRA READ THE FULL YTRA RESEARCH REPORT

Benzinga

BLSTF: Blackstone Minerals PFS on Integrated (both upstream & downstream portions) Ta Khoa Project Completed reflecting management's vertically integrated strategy.

By Steven Ralston, CFA OTC:BLSTF | ASX:BSX READ THE FULL BLSTF RESEARCH REPORT

Benzinga

UCL: uCloudlink Revenues are Still Ready to Surge When International Travel Resumes

By Lisa Thompson NASDAQ:UCL READ THE FULL UCL RESEARCH REPORT

Benzinga

NEXCF: NexTech AR's Mission is to Build the First Vertically Integrated AI-Powered 3D Model Factory for the Metaverse

By Lisa Thompson OTC:NEXCF READ THE FULL NEXCF RESEARCH REPORT

Benzinga

DFFN: Additional Tissue Oxygenation Trial Results Expected Mid-2022…

By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT

Benzinga

A Fireside Chat with Evan Gappelberg - CEO of NexTech AR Solutions

OTC:NEXCF

1 … 4 5 6 7

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.